Study outcomes

Table S5 – Adverse events reported by studies (to be continued)

Osteoporosis from adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	1	59	6,15	0,01 - 4037,00
Discontinuation or dropouts/withdrawals due to adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150/150/200/300 mg/day	1	289	18,05	0,03 - 9868,95
Atazanavir 300 mg/day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	533	81,97	4,16 - 1611,00
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	2	307	61,58	2,14 - 1797,00
Nevirapine 200 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	370	44,25	2,38 - 838,60
Lopinavir/Ritonavir 400/100 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	371	0,31	0,00 - 29,70
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide 800/150/200/10 mg/day	2	184	15,41	0,21 - 876,59
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	41	121,30	0,21 - 67219,50
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day	1	234	0,00	0,00 - 0,20
Efavirenz 600 mg/day + Tenofovir disoproxil fumarate 300 mg/day + Lamivudine 300 mg/day	1	29	0,00	0,00 - 0,48
Efavirenz 600 mg/day + Lamivudine/Zidovudine 150/300 mg 12/12h	1	30	126,40	0,23 - 69389,00
All treatments	15	2388	20,78	5,58 - 57,31
Discontinuation or dropouts/withdrawals due to ART-related adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Nevirapine 200 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	249	44,89	0,09 - 24219,50

Table S5 – Adverse events reported by studies (continuation)

Discontinuation or dropouts/withdrawals due to ART-related adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Lopinavir/Ritonavir 400/100 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	251	0,00	0,00 - 0,06
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide 800/150/200/10 mg/day	2	184	15,41	0,21 - 876,59
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	41	121,30	0,21 - 67219,50
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day	1	234	0,00	0,00 - 0,20
Efavirenz 600 mg/day + Tenofovir disoproxil fumarate 300 mg/day + Lamivudine 300 mg/day	1	29	0,00	0,00 - 0,48
All treatments	7	988	4,31	0,13 - 54,72
Clinical and/or laboratory adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	247	972,10	1,82 - 511395,00
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	1	248	933,00	1,69 - 498690,00
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide 800/150/200/10 mg/day	2	184	922,90	56,88 - 15170,00
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	41	913,40	1,67 - 482400,00
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day	1	234	718,40	1,35 - 375995,00
All treatments	6	954	888,20	759,90 - 1045,00
Clinical and/or laboratory adverse events related to ART				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	247	594,80	1,10 - 318800,00
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	1	248	395,20	0,73 - 211000,00

Table S5 – Adverse events reported by studies (continuation)

Clinical and/or laboratory adverse events related to ART				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide 800/150/200/10 mg/day	2	184	357,80	8,25 - 15370,00
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	41	545,80	0,99 - 304395,00
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day	1	234	91,31	0,17 - 49459,50
All treatments	6	954	341,60	133,60 - 862,70
Clinical adverse events related to ART				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir disoproxil fumarate 150/150/200/300 mg/day	1	289	322,40	0,60 - 174800,00
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	286	570,60	1,07 - 315895,00
All treatments	2	575	431,50	13,84 - 13630,00
Grade 3 and/or 4 clinical and/or laboratory adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Darunavir/Cobicistat/Emtricitabine/ Tenofovir alafenamide 800/150/200/10 mg/day	2	184	80,75	3,16 - 2072,00
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	41	95,23	0,17 - 53989,50
Efavirenz 600 mg/day + Tenofovir disoproxil fumarate 300 mg/day + Lamivudine 300 mg/day	1	29	77,39	0,14 - 42889,50
Efavirenz 600 mg/day + Lamivudine/Zidovudine 150/300 mg 12/12h	1	30	137,80	0,25 - 74109,50
All treatments	5	284	96,34	55,04 - 158,90
Grade 3 and/or 4 clinical adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150/150/200/300 mg/day	1	289	93,37	0,17 - 50589,50

Table S5 – Adverse events reported by studies (continuation)

Grade 3 and/or 4 clinical adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	286	117,60	0,22 - 62379,00
Nevirapine 200 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	370	45,83	2,46 - 876,20
Lopinavir/Ritonavir 400/100 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	371	45,40	1,90 - 1001,00
All treatments	6	1316	59,93	33,74 - 104,60
Grade 3 and/or 4 laboratory adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir disoproxil fumarate 150/150/200/300 mg/day	1	289	251,40	0,46 - 136000,00
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	286	703,70	1,32 - 364000,00
Nevirapine 200 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	370	86,76	5,09 - 1528,00
Lopinavir/Ritonavir 400/100 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	371	71,04	4,07 - 1235,00
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day	1	234	188,80	0,35 - 100900,00
All treatments	7	1550	145,10	57,71 - 359,90
Grade 3 clinical and/or laboratory adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	247	181,00	0,34 - 98849,50
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	1	248	83,97	0,16 - 45879,50
All treatments	2	495	125,50	3,51 - 4295,00

Table S5 – Adverse events reported by studies (continuation)

Grade 4 clinical and/or laboratory adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	247	42,49	0,08 - 23669,50
Grade 4 clinical and/or laboratory adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	1	248	12,36	0,02 - 7240,75
All treatments	2	495	25,05	0,50 - 1017,00
Grade 4 clinical adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Nevirapine 200 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	249	8,60	0,02 - 4567,85
Lopinavir/Ritonavir 400/100 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	251	9,79	0,02 - 5430,00
All treatments	2	500	9,31	0,39 - 216,30
Serious clinical and/or laboratory adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	247	96,95	0,18 - 51859,50
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	2	307	67,41	2,66 - 1763,95
Nevirapine 200 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	370	30,05	1,33 - 637,10
Lopinavir/Ritonavir 400/100 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	371	20,74	0,78 - 491,70
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide 800/150/200/10 mg/day	2	184	40,91	1,16 - 1488,95
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	41	95,23	0,17 - 53989,50

Table S5 – Adverse events reported by studies (continuation)

Serious clinical and/or laboratory adverse events				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day	1	234	30,64	0,06 - 17229,50
Efavirenz 600 mg/day + Tenofovir disoproxil fumarate 300 mg/day + Lamivudine 300 mg/day	1	29	112,10	0,21 - 61089,00
Efavirenz 600 mg/day + Lamivudine/Zidovudine 150/300 mg 12/12h	1	30	126,40	0,23 - 69389,00
All treatments	13	1813	49,34	31,60 - 77,10
Grade 3 and/or 4 clinical and/or laboratory adverse events related to ART				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide 800/150/200/10 mg/day	2	184	21,91	0,47 - 943,60
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	41	42,17	0,06 - 24359,50
All treatments	3	225	27,75	2,56 - 272,90
Serious clinical and/or laboratory adverse events related to ART				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	247	12,70	0,02 - 7228,85
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	1	248	0,00	0,00 - 0,21
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide 800/150/200/10 mg/day	2	184	0,00	0,00 - 0,12
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	41	68,36	0,11 - 39559,00
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day	1	234	0,00	0,00 - 0,20
All treatments	6	954	1,09	0,01 - 21,47

Table S5 – Adverse events reported by studies (continuation)

Serious clinical adverse events related to ART				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150/150/200/300 mg/day	1	289	10,21	0,02 - 5968,00
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	286	18,85	0,03 - 10450,00
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	1	248	0,00	0,00 - 0,21
Serious clinical adverse events related to ART				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Darunavir/Cobicistat/Emtricitabine/ Tenofovir alafenamide 800/150/200/10 mg/day	1	140	0,00	0,00 - 0,35
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day	1	234	0,00	0,00 - 0,20
All treatments	5	1197	1,53	0,01 - 21,29
Death from all causes				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir disoproxil fumarate 150/150/200/300 mg/day	1	289	0,00	0,00 - 0,17
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	533	0,73	0,00 - 60,56
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	2	307	1,04	0,00 - 72,82
Nevirapine 200 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	370	7,87	0,26 - 238,40
Lopinavir/Ritonavir 400/100 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	371	5,75	0,08 - 226,10
Darunavir/Cobicistat/Emtricitabine/ Tenofovir alafenamide 800/150/200/10 mg/day	2	184	0,00	0,00 - 0,09
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	41	0,00	0,00 - 1,07
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day	1	234	0,00	0,00 - 0,20

Table S5 – Adverse events reported by studies (conclusion)

Death from all causes				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Efavirenz 600 mg/day + Tenofovir disoproxil fumarate 300 mg/day + Lamivudine 300 mg/day	1	29	7,30	0,01 - 4814,00
Efavirenz 600 mg/day + Lamivudine/Zidovudine 150/300 mg 12/12h	1	30	7,42	0,01 - 4967,95
All treatments	15	2388	4,47	1,42 - 7,91
Death from adverse events related to ART				
ART	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir disoproxil fumarate 150/150/200/300 mg/day	1	289	0,00	0,00 - 0,17
Atazanavir 300 /day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	533	0,00	0,00 - 0,03
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day	2	307	0,00	0,00 - 0,05
Nevirapine 200 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	370	0,29	0,00 - 20,77
Lopinavir/Ritonavir 400/100 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	2	371	0,94	0,00 - 60,39
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide 800/150/200/10 mg/day	2	184	0,00	0,00 - 0,12
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day	1	41	0,00	0,00 - 1,07
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day	1	234	0,00	0,00 - 0,20
Efavirenz 600 mg/day + Tenofovir disoproxil fumarate 300 mg/day + Lamivudine 300 mg/day	1	29	0,00	0,00 - 0,48
Efavirenz 600 mg/day + Lamivudine/Zidovudine 150/300 mg 12/12h	1	30	0,00	0,00 - 0,49
All treatments	15	2388	0,18	0,00 - 1,56

Table S6 - Adverse events by antiretroviral regimen (to be continued)

Atazanavir 300 mg/day + Ritonavir 100 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Discontinuation due to adverse events	2	533	81,97	4,16 - 1611,00
Clinical and/or laboratory adverse events	1	247	972,10	1,82 - 511395,00
Clinical and/or laboratory adverse events related to ART	1	247	594,80	1,10 - 318800,00
Clinical adverse events related to ART	1	286	570,60	1,07 - 315895,00
Grade 3 and/or 4 clinical adverse events	1	286	117,60	0,22 - 62379,00
Grade 3 and/or 4 laboratory adverse events	1	286	703,70	1,32 - 364000,00
Grade 3 clinical and/or laboratory adverse events	1	247	181,00	0,34 - 98849,50
Grade 4 clinical and/or laboratory adverse events	1	247	42,49	0,08 - 23669,50
Serious clinical and/or laboratory adverse events	1	247	96,95	0,18 - 51859,50
Serious clinical and/or laboratory adverse events related to ART	1	247	12,70	0,02 - 7228,85
Serious clinical adverse events related to ART	1	286	18,85	0,03 - 10450,00
Death from all causes	2	533	0,73	0,00 - 60,56
Death from adverse events related to ART	2	533	0,00	0,00 - 0,03
Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Discontinuation due to adverse events	1	234	0,00	0,00 - 0,20
Discontinuation due to ART-related adverse events	1	234	0,00	0,00 - 0,20
Clinical and/or laboratory adverse events	1	234	718,40	1,35 - 375995,00
Clinical and/or laboratory adverse events related to ART	1	234	91,31	0,17 - 49459,50
Grade 3 and/or 4 laboratory adverse events	1	234	188,80	0,35 - 100900,00
Serious clinical and/or laboratory adverse events	1	234	30,64	0,06 - 17229,50
Serious clinical and/or laboratory adverse events related to ART	1	234	0,00	0,00 - 0,20
Serious clinical adverse events related to ART	1	234	0,00	0,00 - 0,20

Table S6 - Adverse events by antiretroviral regimen (continuation)

Bictegravir/Emtricitabine/Tenofovir alafenamide 50/200/25 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Death from all causes	1	234	0,00	0,00 - 0,20
Death from adverse events related to ART	1	234	0,00	0,00 - 0,20
Darunavir/Cobicistat 800/150 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Discontinuation due to adverse events	1	41	121,30	0,21 - 67219,50
Discontinuation due to ART-related adverse events	1	41	121,30	0,21 - 67219,50
Clinical and/or laboratory adverse events	1	41	913,40	1,67 - 482400,00
Clinical and/or laboratory adverse events related to ART	1	41	545,80	0,99 - 304395,00
Grade 3 and/or 4 clinical and/or laboratory adverse events	1	41	95,23	0,17 - 53989,50
Serious clinical and/or laboratory adverse events	1	41	95,23	0,17 - 53989,50
Grade 3 and/or 4 clinical and/or laboratory adverse events related to ART	1	41	42,17	0,06 - 24359,50
Serious clinical and/or laboratory adverse events related to ART	1	41	68,36	0,11 - 39559,00
Death from all causes	1	41	0,00	0,00 - 1,07
Death from adverse events related to ART	1	41	0,00	0,00 - 1,07
Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide 800/150/200/10 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Discontinuation due to adverse events	2	184	15,41	0,21 - 876,59
Discontinuation due to ART-related adverse events	2	184	15,41	0,21 - 876,59
Clinical and/or laboratory adverse events	2	184	922,90	56,88 - 15170,00
Clinical and/or laboratory adverse events related to ART	2	184	357,80	8,25 - 15370,00
Grade 3 and/or 4 clinical and/or laboratory adverse events	2	184	80,75	3,16 - 2072,00
Serious clinical and/or laboratory adverse events	2	184	40,91	1,16 - 1488,95

Table S6 - Adverse events by antiretroviral regimen (continuation)

Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide 800/150/200/10 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Grade 3 and/or 4 clinical and/or laboratory adverse events related to ART	2	184	21,91	0,47 - 943,60
Serious clinical and/or laboratory adverse events related to ART	2	184	0,00	0,00 - 0,12
Serious clinical adverse events related to ART	1	140	0,00	0,00 - 0,35
Death from all causes	2	184	0,00	0,00 - 0,09
Death from adverse events related to ART	2	184	0,00	0,00 - 0,12
Dolutegravir/Abacavir/Lamivudine 50/600/300 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Osteoporosis from adverse events	1	59	6,15	0,01 - 4037,00
Discontinuation due to adverse events	2	307	61,58	2,14 - 1797,00
Clinical and/or laboratory adverse events	1	248	933,00	1,69 - 498690,00
Clinical and/or laboratory adverse events related to ART	1	248	395,20	0,73 - 211000,00
Grade 3 clinical and/or laboratory adverse events	1	248	83,97	0,16 - 45879,50
Grade 4 clinical and/or laboratory adverse events	1	248	12,36	0,02 - 7240,75
Serious clinical and/or laboratory adverse events	2	307	67,41	2,66 - 1763,95
Serious clinical and/or laboratory adverse events related to ART	1	248	0,00	0,00 - 0,21
Serious clinical adverse events related to ART	1	248	0,00	0,00 - 0,21
Death from all causes	2	307	1,04	0,00 - 72,82
Death from adverse events related to ART	2	307	0,00	0,00 - 0,05
Efavirenz 600 mg/day + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Laboratory adverse events	1	242	40,55	0,08 - 21369,50

Table S6 - Adverse events by antiretroviral regimen (continuation)

Efavirenz 600 mg/day + Tenofovir disoproxil fumarate 300 mg/day + Lamivudine 300 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Discontinuation due to adverse events	1	29	0,00	0,00 - 0,48
Discontinuation due to ART-related adverse events	1	29	0,00	0,00 - 0,48
Grade 3 and/or 4 clinical and/or laboratory adverse events	1	29	77,39	0,14 - 42889,50
Serious clinical and/or laboratory adverse events	1	29	112,10	0,21 - 61089,00
Death from all causes	1	29	7,30	0,01 - 4814,00
Death from adverse events related to ART	1	29	0,00	0,00 - 0,48
Efavirenz 600 mg/day + Lamivudine/Zidovudine 150/300 mg 12/12h				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Discontinuation due to adverse events	1	30	126,40	0,23 - 69389,00
Laboratory adverse events	1	241	65,60	0,12 - 36399,50
Grade 3 and/or 4 clinical and/or laboratory adverse events	1	30	137,80	0,25 - 74109,50
Serious clinical and/or laboratory adverse events	1	30	126,40	0,23 - 69389,00
Death from all causes	1	30	7,42	0,01 - 4967,95
Death from adverse events related to ART	1	30	0,00	0,00 - 0,49
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir disoproxil fumarate 150/150/200/300 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Discontinuation due to adverse events	1	289	18,05	0,03 - 9868,95
Clinical adverse events related to ART	1	289	322,40	0,60 - 174800,00
Grade 3 and/or 4 clinical adverse events	1	289	93,37	0,17 - 50589,50
Grade 3 and/or 4 laboratory adverse events	1	289	251,40	0,46 - 136000,00
Serious clinical adverse events related to ART	1	289	10,21	0,02 - 5968,00
Death from all causes	1	289	0,00	0,00 - 0,17
Death from adverse events related to ART	1	289	0,00	0,00 - 0,17

Table S6 - Adverse events by antiretroviral regimen (continuation)

Lopinavir/Ritonavir 400/100 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Discontinuation due to adverse events	2	371	0,31	0,00 - 29,70
Discontinuation due to ART-related adverse events	1	251	0,00	0,00 - 0,06
Grade 3 and/or 4 clinical adverse events	2	371	45,40	1,90 - 1001,00
Grade 3 and/or 4 laboratory adverse events	2	371	71,04	4,07 - 1235,00
Grade 4 clinical adverse events	1	251	9,79	0,02 - 5430,00
Serious clinical and/or laboratory adverse events	2	371	20,74	0,78 - 491,70
Death from all causes	2	371	5,75	0,08 - 226,10
Death from adverse events related to ART	2	371	0,94	0,00 - 60,39
Nevirapine 200 mg 12/12h + Emtricitabine/Tenofovir disoproxil fumarate 200/300 mg/day				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Discontinuation due to adverse events	2	370	44,25	2,38 - 838,60
Discontinuation due to ART-related adverse events	1	249	44,89	0,09 - 24219,50
Grade 3 and/or 4 clinical adverse events	2	370	45,83	2,46 - 876,20
Grade 3 and/or 4 laboratory adverse events	2	370	86,76	5,09 - 1528,00
Grade 4 clinical adverse events	1	249	8,60	0,02 - 4567,85
Serious clinical and/or laboratory adverse events	2	370	30,05	1,33 - 637,10
Death from all causes	2	370	7,87	0,26 - 238,40
Death from adverse events related to ART	2	370	0,29	0,00 - 20,77
All treatments				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Discontinuation due to adverse events	15	2388	20,78	5,58 - 57,31
Discontinuation due to ART-related adverse events	7	988	4,31	0,13 - 54,72
Clinical and/or laboratory adverse events	6	954	888,20	759,90 - 1045,00
Laboratory adverse events	2	483	52,02	1,89 - 1388,00
Clinical and/or laboratory adverse events related to ART	6	954	341,60	133,60 - 862,70

Table S6 - Adverse events by antiretroviral regimen (continuation)

All treatments				
Outcome	Number of study arms	Number of women	Incidence rate (number of events/1000 person-years)	Credibility interval (95%)
Clinical adverse events related to ART	2	575	431,50	13,84 - 13630,00
Grade 3 and/or 4 clinical and/or laboratory adverse events	5	284	96,34	55,04 - 158,90
Grade 3 and/or 4 clinical adverse events	6	1316	59,93	33,74 - 104,60
Grade 3 and/or 4 laboratory adverse events	7	1550	145,10	57,71 - 359,90
Grade 3 clinical and/or laboratory adverse events	2	495	125,50	3,51 - 4295,00
Grade 4 clinical and/or laboratory adverse events	2	495	25,05	0,50 - 1017,00
Grade 4 clinical adverse events	2	500	9,31	0,39 - 216,30
Serious clinical and/or laboratory adverse events	13	1813	49,34	31,60 - 77,10
Grade 3 and/or 4 clinical and/or laboratory adverse events related to ART	3	225	27,75	2,56 - 272,90
Serious clinical and/or laboratory adverse events related to ART	6	954	1,09	0,01 - 21,47
Serious clinical adverse events related to ART	5	1197	1,53	0,01 - 21,29
Death from all causes	15	2388	4,47	1,42 - 7,91
Death from adverse events related to ART	15	2388	0,18	0,00 - 1,56